A Study of SHR-A1811 in Subjects With Ovarian Cancer
ConditionOvarian Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorJiangsu HengRui Medicine Co., Ltd.
About this trial
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
Eligibility criteria
Qualifiers
The subjects voluntarily joined the study and signed the Informed consent forms (ICF).
Measurable disease, as defined by RECIST v1.1.
The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.
Life expectancy ≥ 12 weeks.
Disqualifiers
Symptomatic, untreated or active central nervous system metastases.
Have uncontrolled or severe cardiovascular disease.
With any active autoimmune disease or history of autoimmune disease.
Patients with active hepatitis B or hepatitis C.
Trial design
Treatments tested in this trial
- SHR-A1811
- Paclitaxel Injection
- Doxorubicin Hydrochloride Liposome Injection
- Gemcitabine Hydrochloride for Injection
- Topotecan Hydrochloride for Injection
Treatment groups
300 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov